Ryan Deschner
Stock Analyst at Raymond James
(1.89)
# 1,883
Out of 4,667 analysts
6
Total ratings
50%
Success rate
-9.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRVI Trevi Therapeutics | Initiates: Outperform | $9 | $2.77 | +224.91% | 1 | Aug 30, 2024 | |
| LQDA Liquidia | Upgrades: Strong Buy | $27 | $10.12 | +166.80% | 2 | Aug 19, 2024 | |
| SPRY ARS Pharmaceuticals | Upgrades: Strong Buy | $18 → $22 | $13.55 | +62.36% | 2 | Aug 13, 2024 | |
| OMGA Omega Therapeutics | Initiates: Outperform | $12 | $0.79 | +1,418.60% | 1 | Jun 18, 2024 |
Trevi Therapeutics
Aug 30, 2024
Initiates: Outperform
Price Target: $9
Current: $2.77
Upside: +224.91%
Liquidia
Aug 19, 2024
Upgrades: Strong Buy
Price Target: $27
Current: $10.12
Upside: +166.80%
ARS Pharmaceuticals
Aug 13, 2024
Upgrades: Strong Buy
Price Target: $18 → $22
Current: $13.55
Upside: +62.36%
Omega Therapeutics
Jun 18, 2024
Initiates: Outperform
Price Target: $12
Current: $0.79
Upside: +1,418.60%